Forte Biosciences, Inc.

NasdaqCM:FBRX Stock Report

Market Cap: US$33.2m

Forte Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Paul A. Wagner

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage42.7%
CEO tenure7yrs
CEO ownership5.3%
Management average tenure3.2yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

CEO Compensation Analysis

How has Paul A. Wagner's remuneration changed compared to Forte Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$34m

Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$1mUS$620k

-US$31m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$590k

-US$14m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$5mUS$590k

-US$22m

Sep 30 2021n/an/a

-US$23m

Jun 30 2021n/an/a

-US$20m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$777kUS$453k

-US$46m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$525kUS$350k

-US$4m

Compensation vs Market: Paul A.'s total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD649.25K).

Compensation vs Earnings: Paul A.'s compensation has increased whilst the company is unprofitable.

CEO

Paul A. Wagner (54 yo)

7yrs

Tenure

US$1,450,175

Compensation

Dr. Paul A. Wagner, CFA, Ph.D. has been the Senior Vice President of Corporate Strategy & Development and Chief Business Officer at CANbridge Life Sciences Ltd. since October 16, 2017. Dr. Wagner leads CAN...

Leadership Team

NamePositionTenureCompensationOwnership
Paul A. Wagner
CEO, President & Chairman7yrsUS$1.45m5.3%
$ 1.8m
Antony Riley
Chief Financial Officer4.8yrsUS$722.98k2.11%
$ 698.9k
Barbara Finck
Chief Medical Clinician & Directorless than a yearUS$61.73k0%
$ 0
Christopher Roenfeldt
Chief Operating Officer2.7yrsno datano data
Steven Ruhl
Chief Technical Officer3.2yrsno datano data

3.2yrs

Average Tenure

62yo

Average Age

Experienced Management: FBRX's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul A. Wagner
CEO, President & Chairman8yrsUS$1.45m5.3%
$ 1.8m
Barbara Finck
Chief Medical Clinician & Director2.8yrsUS$61.73k0%
$ 0
David Gryska
Independent Director2yrsUS$104.30k0.41%
$ 134.9k
Richard Vincent
Independent Directorless than a yearno datano data
Patricia Walker
Member of Scientific Advisory Boardno dataUS$50.80kno data
Stephen Doberstein
Member of Scientific Advisory Board & Independent Director2.7yrsUS$62.73k0%
$ 0
Steven Kornfeld
Independent Director4.6yrsUS$97.73k0.27%
$ 89.9k
Shivpreet Kapoor
Independent Directorless than a yearno datano data
Scott Brun
Independent Director2.2yrsUS$62.73k0%
$ 0
Eric Simpson
Member of Scientific Advisory Boardno datano datano data

2.4yrs

Average Tenure

60yo

Average Age

Experienced Board: FBRX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 23:03
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Forte Biosciences, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets
Keay NakaeChardan Capital Markets, LLC